Compare AstraZeneca plc (AZN) vs Morgan Stanley (MS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Morgan Stanley — how do they compare? AstraZeneca plc trades at $158.97 (market cap $250.84B), while Morgan Stanley trades at $215.39 (market cap $338.50B). The key difference: Morgan Stanley is the larger of the two by market cap, and Morgan Stanley pays the higher dividend (2.14%). Which is the better fit depends on your goals.
| AZN | MS | |
|---|---|---|
Market Cap | $250.84B | $338.50B |
Sector | Health | Financials |
52-Week High | $209.48 | $228.42 |
52-Week Low | $147.06 | $143.88 |
Enterprise Value | $278.12B | — |
Dividend Yield | 1.97% | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.42, up 0.22% today, amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth to $58.74B in 2025 and net income of $10.23B, supported by a P/E of 24.16 and robust profitability margins. Recent news highlights potential talks with Bristol Myers Squibb, though a senior source denied ongoing discussions (Reuters, 2026-08-05).
The outlook is mixed: solid earnings beats and a 47.5% analyst buy rating support upside, but technical weakness and merger uncertainty pose near-term risks. Long-term growth hinges on execution amid competitive and regulatory pressures, with the stock offering value if merger rumors subside and fundamentals prevail.
Morgan Stanley (MS) trades at $216.26, up 1.18% with a bullish technical outlook and strong earnings beats in recent quarters. Revenue grew to $66.0B in 2025, with net income margin expanding to 25.56%. The stock is supported by analyst consensus price target of $239.58 and recent news of leading Anthropic's IPO, indicating robust business momentum.
Outlook remains positive given earnings growth and institutional support, but risks include volatile cash flows and high debt levels. The stock offers upside to consensus targets, though investors should monitor interest expense impacts and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Morgan Stanley
Morgan Stanley is a global investment bank whose history, through its legacy firms, can be traced back to 1924. The company has institutional securities, wealth management, and investment management segments. The company had about $5 trillion of client assets as well as over 70,000 employees at the end of 2021. Approximately 50% of the company's net revenue is from its institutional securities business, with the remainder coming from wealth and investment management. The company derives about 30% of its total revenue outside the Americas.
Read more on MS →
